vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and FIRST MID BANCSHARES, INC. (FMBH). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $88.2M, roughly 1.6× FIRST MID BANCSHARES, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 26.8%, a 8.6% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 3.4%). FIRST MID BANCSHARES, INC. produced more free cash flow last quarter ($124.0M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 5.0%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
First Mid Bancshares Inc. is a U.S.-headquartered regional financial services holding company. It provides full-range retail and commercial banking products, wealth management, insurance solutions, and agricultural financing, mainly serving individual consumers, small and medium-sized enterprises, and agricultural clients across multiple Midwestern states including Illinois, Missouri, and Indiana.
ADMA vs FMBH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $88.2M |
| Net Profit | $49.4M | $23.7M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 34.0% |
| Net Margin | 35.5% | 26.8% |
| Revenue YoY | 18.4% | 3.4% |
| Net Profit YoY | -55.9% | 23.5% |
| EPS (diluted) | $0.20 | $0.98 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $88.2M | ||
| Q3 25 | $134.2M | $89.3M | ||
| Q2 25 | $122.0M | $87.5M | ||
| Q1 25 | $114.8M | $84.3M | ||
| Q4 24 | $117.5M | $85.3M | ||
| Q3 24 | $119.8M | $80.6M | ||
| Q2 24 | $107.2M | $79.2M | ||
| Q1 24 | $81.9M | $79.9M |
| Q4 25 | $49.4M | $23.7M | ||
| Q3 25 | $36.4M | $22.5M | ||
| Q2 25 | $34.2M | $23.4M | ||
| Q1 25 | $26.9M | $22.2M | ||
| Q4 24 | $111.9M | $19.2M | ||
| Q3 24 | $35.9M | $19.5M | ||
| Q2 24 | $32.1M | $19.7M | ||
| Q1 24 | $17.8M | $20.5M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 34.0% | ||
| Q3 25 | 38.0% | 32.2% | ||
| Q2 25 | 35.1% | 34.4% | ||
| Q1 25 | 30.4% | 33.4% | ||
| Q4 24 | 32.6% | 29.7% | ||
| Q3 24 | 33.1% | 31.5% | ||
| Q2 24 | 36.6% | 33.7% | ||
| Q1 24 | 26.7% | 33.7% |
| Q4 25 | 35.5% | 26.8% | ||
| Q3 25 | 27.1% | 25.2% | ||
| Q2 25 | 28.1% | 26.8% | ||
| Q1 25 | 23.4% | 26.3% | ||
| Q4 24 | 95.2% | 22.5% | ||
| Q3 24 | 30.0% | 24.2% | ||
| Q2 24 | 29.9% | 24.9% | ||
| Q1 24 | 21.7% | 25.6% |
| Q4 25 | $0.20 | $0.98 | ||
| Q3 25 | $0.15 | $0.94 | ||
| Q2 25 | $0.14 | $0.98 | ||
| Q1 25 | $0.11 | $0.93 | ||
| Q4 24 | $0.45 | $0.81 | ||
| Q3 24 | $0.15 | $0.81 | ||
| Q2 24 | $0.13 | $0.82 | ||
| Q1 24 | $0.08 | $0.86 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | $354.5M |
| Stockholders' EquityBook value | $477.3M | $958.7M |
| Total Assets | $624.2M | $8.0B |
| Debt / EquityLower = less leverage | 0.15× | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | — | ||
| Q1 24 | $45.3M | — |
| Q4 25 | $72.1M | $354.5M | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $958.7M | ||
| Q3 25 | $431.2M | $932.2M | ||
| Q2 25 | $398.3M | $894.1M | ||
| Q1 25 | $373.4M | $870.9M | ||
| Q4 24 | $349.0M | $846.4M | ||
| Q3 24 | $231.9M | $858.5M | ||
| Q2 24 | $188.3M | $813.6M | ||
| Q1 24 | $153.7M | $798.0M |
| Q4 25 | $624.2M | $8.0B | ||
| Q3 25 | $568.7M | $7.8B | ||
| Q2 25 | $558.4M | $7.7B | ||
| Q1 25 | $510.6M | $7.6B | ||
| Q4 24 | $488.7M | $7.5B | ||
| Q3 24 | $390.6M | $7.6B | ||
| Q2 24 | $376.4M | $7.6B | ||
| Q1 24 | $350.9M | $7.7B |
| Q4 25 | 0.15× | 0.37× | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $130.9M |
| Free Cash FlowOCF − Capex | $34.6M | $124.0M |
| FCF MarginFCF / Revenue | 24.8% | 140.6% |
| Capex IntensityCapex / Revenue | 0.8% | 7.8% |
| Cash ConversionOCF / Net Profit | 0.72× | 5.53× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $207.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $130.9M | ||
| Q3 25 | $13.3M | $33.0M | ||
| Q2 25 | $21.1M | $7.7M | ||
| Q1 25 | $-19.7M | $47.9M | ||
| Q4 24 | $50.2M | $124.4M | ||
| Q3 24 | $25.0M | $33.1M | ||
| Q2 24 | $45.6M | $24.0M | ||
| Q1 24 | $-2.2M | $29.0M |
| Q4 25 | $34.6M | $124.0M | ||
| Q3 25 | $-1.1M | $31.9M | ||
| Q2 25 | $18.7M | $6.0M | ||
| Q1 25 | $-24.4M | $46.0M | ||
| Q4 24 | $47.5M | $119.5M | ||
| Q3 24 | $24.0M | $32.0M | ||
| Q2 24 | $43.6M | $22.9M | ||
| Q1 24 | $-4.6M | $27.6M |
| Q4 25 | 24.8% | 140.6% | ||
| Q3 25 | -0.8% | 35.8% | ||
| Q2 25 | 15.3% | 6.8% | ||
| Q1 25 | -21.2% | 54.5% | ||
| Q4 24 | 40.4% | 140.0% | ||
| Q3 24 | 20.0% | 39.7% | ||
| Q2 24 | 40.7% | 28.9% | ||
| Q1 24 | -5.6% | 34.5% |
| Q4 25 | 0.8% | 7.8% | ||
| Q3 25 | 10.7% | 1.2% | ||
| Q2 25 | 2.0% | 2.0% | ||
| Q1 25 | 4.1% | 2.3% | ||
| Q4 24 | 2.3% | 5.8% | ||
| Q3 24 | 0.9% | 1.4% | ||
| Q2 24 | 1.9% | 1.4% | ||
| Q1 24 | 2.9% | 1.9% |
| Q4 25 | 0.72× | 5.53× | ||
| Q3 25 | 0.36× | 1.47× | ||
| Q2 25 | 0.62× | 0.33× | ||
| Q1 25 | -0.73× | 2.16× | ||
| Q4 24 | 0.45× | 6.49× | ||
| Q3 24 | 0.70× | 1.70× | ||
| Q2 24 | 1.42× | 1.21× | ||
| Q1 24 | -0.12× | 1.42× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
FMBH
Segment breakdown not available.
